{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.0","upperLimit":"85.0","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received one 4 mg Baricitinib tablet administered orally QD.","id":"OG000","title":"4 mg Baricitinib Phase 3 Open-Label Addendum"}],"paramType":"NUMBER","populationDescription":"All randomized phase 3 open-label addendum participants with baseline ClinRO measure for EB Hair Loss ≥ 2 and who had evaluable data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 52","title":"Percentage of Participants Achieving ClinRO Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum","type":"SECONDARY","unitOfMeasure":"percentage of participants"}